Sign in to continue:

Saturday, March 21st, 2026

NextNRG, Inc. Receives Nasdaq Delisting Notice for Non-Compliance with $1.00 Minimum Bid Price Requirement

NextNRG, Inc. Receives Nasdaq Notice for Non-Compliance with Minimum Bid Price Rule

Key Points:

  • NextNRG, Inc. (NASDAQ: NXXT) has received a formal notification from the Nasdaq Listing Qualifications Department indicating non-compliance with the \$1.00 minimum bid price requirement.
  • This requirement is set forth in Nasdaq Listing Rule 5550(a)(2), which mandates that listed companies must maintain a minimum bid price of \$1.00 per share to remain on the Nasdaq Capital Market.
  • The notice was received on March 16, 2026, and relates to the Company’s common stock currently traded under the symbol “NXXT”.
  • Despite the notice, NextNRG’s shares will continue to trade as usual on the Nasdaq Capital Market for now.

Details Investors Should Know:

  • No Immediate Delisting: The Nasdaq notification does not immediately affect the listing or trading of NextNRG’s common stock. Shares will continue to trade under “NXXT” while the Company works to resolve the deficiency.
  • Compliance Period: NextNRG has 180 calendar days to regain compliance with the minimum bid price requirement. If the stock price closes at \$1.00 or more for at least 10 consecutive business days during this period, the Company will return to compliance.
  • Second Compliance Window: If NextNRG does not regain compliance within the initial 180 days but continues to meet other listing requirements (such as market value of publicly held shares and other standards), it may be eligible for an additional 180-day extension. To qualify for the extension, the Company must notify Nasdaq of its intent to cure the deficiency, potentially via a reverse stock split.
  • Potential Actions: The Company is actively monitoring its stock price and evaluating possible actions, including a reverse stock split or other alternatives, to regain compliance. However, no decisions have been made yet.
  • Risk Factors: There is no assurance that NextNRG will be able to regain compliance. Failure to do so could ultimately lead to delisting from Nasdaq Capital Market, which would likely have a significant negative impact on share value, liquidity, and investor confidence.
  • Emerging Growth Company: NextNRG is designated as an “emerging growth company” under SEC rules, which may affect its regulatory requirements and reporting standards.

Items Filed:

  • Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • Item 9.01: Financial Statements and Exhibits
  • Exhibit 104: Cover Page Interactive Data File (embedded within the Inline XBRL document)

Shareholder Impact:

  • This notice is potentially price sensitive as it highlights a risk of delisting, which could lead to reduced market liquidity and a loss of investor confidence.
  • Investors should monitor any further announcements from the Company regarding remedial actions, including potential reverse stock splits, as these could materially affect share value.
  • The Company’s ability to maintain its Nasdaq listing is crucial for its visibility, access to capital, and overall market reputation.

Conclusion: NextNRG, Inc. faces a critical challenge in maintaining its Nasdaq listing due to its share price falling below \$1.00. Shareholders should be aware of the risks and closely follow developments as the Company evaluates alternatives to resolve the deficiency. Failure to comply may lead to delisting, making this a highly material event for investors.


Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions. The information is based on a Form 8-K filing and is subject to change as new details emerge.

View NEXTNRG, INC. Historical chart here



OrthoPediatrics Corp: Comprehensive Pediatric Orthopedic Implants, Bracing, and Innovation Overview (2025)

OrthoPediatrics Corp. 2025 Annual Report - Investor Analysis...

   Ad